TY - JOUR
T1 - Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease
AU - Sivalingam, Zenthuja
AU - Larsen, Sanne Bøjet
AU - Grove, Erik Lerkevang
AU - Hvas, Anne-Mette
AU - Kristensen, Steen Dalby
AU - Magnusson, Nils Erik
PY - 2017
Y1 - 2017
N2 - Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.
AB - Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.
KW - Journal Article
KW - Review
U2 - 10.1515/cclm-2017-0120
DO - 10.1515/cclm-2017-0120
M3 - Review
C2 - 28672731
SN - 1434-6621
VL - 56
SP - 5
EP - 18
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 1
ER -